> This article summarizes and credits reporting from the Good Work YouTube channel's video on peptides, hosted by Dan Toomey. All quotes, interview material, and on the ground reporting featured here are drawn from that video. We strongly recommend watching the original for full context.
Peptides have moved from bodybuilding gyms and Silicon Valley group chats into the broader cultural conversation, and the Good Work YouTube channel recently took a thorough look at what they actually are, who is using them, and whether any of this is a good idea. Here is a summary of the key takeaways.
What Peptides Actually Are
As Good Work explains, peptides are short chains of amino acids that help the body perform a range of functions, from healing muscle tears to growing skin cells to producing hormones like testosterone. The body manufactures many peptides naturally from dietary protein. Familiar examples include insulin and oxytocin.
The "peptides" that have become a cultural flashpoint are different. These are synthetic versions made in labs and injected directly into the body. The most well known are GLP-1 drugs like Ozempic and Wegovy, which are FDA approved and prescribed for weight loss and diabetes. The popularity of GLP-1s has fueled a wider search for other injectable peptides that might deliver other health benefits.
The Long, Confusing List
According to Good Work, peptide users often talk about compounds like BPC-157 (claimed to repair muscle), GHK-Cu (claimed to reduce wrinkles), Dihexa (claimed to improve focus), and Ipamorelin (claimed to improve sleep). Some users mix several into "stacks," sometimes branded with marketing friendly names like the "Wolverine Stack" or the "Glow Stack."
Most of these compounds are not FDA approved for the uses being promoted. The FDA has flagged some peptides as potentially harmful. Because of social media moderation, influencers often refer to them as "peppers" online.
The Chinese Supply Chain
Good Work's reporting describes how most non FDA approved peptides reach American users. Reporter Ezra Marcus, featured in the video, recounts going on the Peptides subreddit, getting invited to a Discord, and finding a representative from a Chinese manufacturer selling directly to users. He purchased ten vials of Retatrutide for about $150 in Bitcoin. The shipment arrived two weeks later, labeled "for research purposes only."
Independent reporter Jasmine Sun, who has written about the trend for The New York Times, told Good Work that peptides emerged as a viral San Francisco meme around mid 2025. In tech culture, she says, having a "Chinese peptide dealer" became a status symbol alongside coding agents and Waymos. The framing was about being an early adopter willing to accept some risk to get an edge.
The economics are striking. Good Work reports that a vial that retails for around $200 through middlemen often costs about $15 to manufacture in China. By Marcus's estimate, billions of dollars are being made flipping these compounds to American consumers.
Why People Are Trying Them
The video features Tori Pastore, founder of the marketing consultancy "soup," who has hosted a peptide themed rave in San Francisco. She tells Good Work that she turned to unregulated peptides after her insurance refused to cover Ozempic because her BMI was 34.7 rather than the required 35. A friend started sourcing from Chinese labs and using himself as a test subject before sharing with others.
Pastore describes serious early side effects, including months of vomiting, but says the trade off was worth it. She has also experimented with copper peptides, which she stopped after a month due to copper toxicity concerns.
Max Marchione, co founder of the health startup Superpower, is more bullish. He tells Good Work he believes peptides could become a $1 trillion category and frames the trend as "Pharma 2.0." He also acknowledges the risks and says he does not recommend that people blindly order peptides from "research use only" sites online.
The Skeptical View
Good Work also features Eric Topol, cardiologist and director of the Scripps Research Translational Institute. Topol is sharply critical of the unregulated peptide market. His core point, as he tells Good Work: there are no real clinical trials supporting most of these uses, and word of mouth, longevity clinic promotion, and influencer testimonials are not science. Without controlled trials, users cannot know whether their results are real, placebo driven, or masking harm. He emphasizes that any injectable drug should be proven safe, accurate to its label, and effective before patients use it.
